Last reviewed · How we verify
Baxdela — Competitive Intelligence Brief
marketed
Fluoroquinolone Antibacterial
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Baxdela (DELAFLOXACIN) — Melinta. Baxdela works by blocking bacterial enzymes that replicate DNA.
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Baxdela TARGET | DELAFLOXACIN | Melinta | marketed | Fluoroquinolone Antibacterial | 2017-01-01 | |
| Levaquin | levofloxacin | Generic (originally Daiichi Sankyo/J&J) | marketed | Fluoroquinolone Antibacterial [EPC] | CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2 | 1996-12-20 |
| Levaquin | Levofloxacin | Santen | marketed | Fluoroquinolone Antibacterial [EPC] | Multidrug and toxin extrusion protein 1 | 1996-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Fluoroquinolone Antibacterial class)
- Melinta · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Baxdela CI watch — RSS
- Baxdela CI watch — Atom
- Baxdela CI watch — JSON
- Baxdela alone — RSS
- Whole Fluoroquinolone Antibacterial class — RSS
Cite this brief
Drug Landscape (2026). Baxdela — Competitive Intelligence Brief. https://druglandscape.com/ci/delafloxacin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing